Objective: To evaluate the effect of imatinib mesylate on cell viability, anti cancer effect through modulation of KAI1/CD82 gene expression in breast cancer MCF-7 cell line. Methods: The effects of imatinib mesylate on cell viability in MCF-7 cell line were assessed using MTT assay and IC 50 value was determined. GAPDH and KAI1/CD82 were selected as reference and target genes, respectively. Quantitative real time PCR technique was applied for investigation of KAI1/CD82 gene expression in human breast cancer MCF-7 cells. Subsequently, the quantity of KAI1 compared to GAPDH gene expressions were analyzed using the formula; 2 −DDCt .
Introduction
Breast cancer is the second leading cause of cancer related death worldwide among women [1, 2] . The high mortality and morbidity associated with breast cancer derived from its metastasis to liver, bone and lungs. The failure of conventional chemo-and radiotherapy and increasing rate of death caused by invasive breast cancer requires an urgent need to identify novel anti cancer drug and new targets for more profitable treatments [3] . Currently, different preclinical and clinical studies on molecular targeted therapies agents have shown that it has great promise in the treatment of different malignant tumors like breast cancer [4] . Imatinib mesylate (IM) (Gleevec; Novartis, Basel, Switzerland), was first used as a novel class of agents that suppress particular tyrosine kinases. IM has been registered in adults for monotherapy of chronic myeloid leukemia by inhibiting specific tyrosine kinases like Bcr-Abl kinase, as well as inhibiting the induction of c-kit receptor kinases and platelet-derived growth factor (ab) receptor which regulate majority of cellular events [5] [6] [7] . Moreover, IM is an important targeted therapy agent used widely for inhibition of tumor growth in several malignancies including ovarian, pancreatic, osteosarcoma, myeloid, thyroid and lung cancer and is recently utilized in research and treatment of other solid tumors [8, 9] . Metastasis to bone is a common complication of cancer patients, with up to 70% of patients due to malignant cancer [10] . Understanding the gene expression during progression of tumor has been the topic of intense method for inhibition of tumor growth and targeting metastatic cascade. Currently, metastasis suppressor genes are found to play an important role in regulation of cell invasion and metastasis signaling. KAI1 (CD82), a tumor metastasis suppressor gene, has wide-spectrum roles in targeting tumor metastasis [11, 12] . Many studies have confirmed that the KAI1/CD82 gene inhibits metastasis in various types of cancers such as endometrial, pancreatic, bladder, breast, ovarian, cervical, lung, hepatic, colorectal and gastric cancer [13] [14] [15] . The main purpose of this study is to determine the effect of various imatinib concentrations on cell viability and metastasis through modulation of KAI1/ CD82 gene expression in breast cancer MCF-7 cell line.
Materials and methods

Cell culture
The human breast adenocarcinoma cell line (MCF-7) was purchased from the National Cell Bank of Iran, Pasteur Institute, Tehran, Iran. Cells were maintained in RPMI 1640 medium that was supplemented with 10% fetal bovine serum, 1 mmol/L sodium pyruvate, 2 mmol/L glutamine, 1% penicillin/streptomycin (all purchase from Gibco, Scotland) in an incubator environment of 5% carbon dioxide (CO 2 ) atmosphere at 37 C.
Cell viability assay
To determine cell viability, we used the MTT assay [12] . Different concentrations of imatinib ranging from 0, 1.5, 2.5, Viability ð%Þ = OD value of samples OD value of controls × 100
The IC 50 value of IM was calculated as the dose at with 50% cell death occurred relative to the untreated cells.
RNA isolation and cDNA synthesis
MCF-7 cell line was seeded in 96 well plate with 5 × 10 4 cells per well and incubated for overnight, and then, the cells were treated with IM. Total RNA was extracted using the RNAisolation kit (Qiagen, RNease Plus Mini Kit 50) according to the manufacturer's instructions. The purity of the isolated RNA has been performed by using a NanoDrop machine (IMPLEN, Germany). RNA isolated with 260/280 nm absorption ratio >1.8 was subjected for cDNA synthesis. Complementary DNA synthesis was amplified using Prime Script™ 1st strand cDNA synthesis kit (Takara, Japan) in 20 mL reaction mixture containing 4 mL Prime Script™ Buffer 5×, 3 mL of total RNA (1 mg), 10 mmol/L dNTPs (1 mL), 50 mmol/L oligo dT primer (1 mL), 50 mmol/L Random 6 mers (1 mL), 1 mL Prime Script™ RTase (200 units), 1 mL RNase inhibitor (40 units) and 8 mL nuclease-free water. Relative quantitation of gene expression was measured by ABI 2720 thermal cycler (Applied Biosystems, USA) for 10 min at 30 C, 50 min at 42 C and 5 min at 95 C followed by cooling on ice for 5 min.
Primer design
In the present investigation, the primers for real-time PCR of GAPDH and KAI1 genes were designed using Primer Express software v3.0.1. The forward and reverse primers used for KAI1/ CD82 gene were the (5 0 CTCAGCCTGTATCAAAGTCACCA 3 0 ) and (5 0 CCCACGCCGATGAAGACATA 3 0 ), respectively.
The sequence of the forward primer for reference gene GAPDH was 5 0 CGTCTGCCCTATCAACTTTCG 3 0 and that of reverse primer was 5 0 CGTTTCTCAGGCTCCCTCT 3 0 . The specificity of the selected primers was tested using BLAST tool (www. ncbi.nlm.nih.gov/blast).
Quantitative data analysis of real-time PCR
A SYBR Green real-time PCR was performed on cDNA isolated from MCF-7 cells after treatment with IM. The expression of target gene was quantified by using an ABI 7300 real-time PCR system, according to the following conditions: 95 C for 10 min, 40
cycles were followed at 95 C for 15 s and 60 C for 1 min. ). Where
Gel electrophoresis was used to approve the amplification of PCR products and primer specificity. The fragments of PCR products were separated by electrophoresis in 1.5% agarose gels in 0.5× tetrabromoethane buffer.
Statistical analysis
The experimental data were performed at least in triplicate and results were expressed as mean ± SEM. P-values <0.05
were considered statistically significant and this was assessed using student's t-test between sample and control. 
Results
MTT assay results
Different
Melting curve analysis and gel electrophoresis
The melting curve analysis was evaluated based on DRn derivation (derivative of fluorescence over temperature) (y axis) and the temperature at x axis. It was created to document single reaction formation without non-specific products and screen for primer dimmers of desired genes. The melting peaks have been drawn at 81.1 C for KAI1/CD82 gene and 82.4 C GAPDH gene as shown in Figure 2A . Moreover, gel electrophoresis analysis of PCR product revealed specific amplification of genes with the expected size ( Figure 2B ). 
Relative quantification analysis using amplification plots
Discussion
Over a million women throughout the world each year are diagnosed with breast cancer which accounts for 25% of all female cancers. The most frequent localization of tumor cells in metastasis such as liver, bone and lungs are dangerous during malignancy of breast cancer. Metastases to bone from breast cancer affect 65-80 percent of patients with progressive malignancy [16] . Imatinib is one of the most widely used tyrosine kinases inhibitors for the treatment of certain cancers that often induce apoptosis and slow progression growth of bone metastases in neoplastic cells which has been recently under examination in clinical trials for malignant gliomas, carcinoid tumor, prostate and ovarian cancer [17] . IM interferes with a specific molecular target included in progression and tumor growth. These targets such as cell-cycle proteins, growth factor receptors, signaling molecules, modulators of apoptosis, and molecules involved in invasion and angiogenesis, which are necessary for development in normal tissues. Nowadays, many researchers showed the invitro cytotoxicity effects of imatinib on various cancer cell lines [18] . In the present study, we demonstrated that IM exerted a dose-dependent inhibitory effect on the viability of highly metastatic breast adenocarcinoma (MCF-7) cells. Treatment of MCF-7 cells with IM induced the morphological changes which revealed the increase in apoptotic cell population. Tumor metastasis is the most lethal characteristic of a cancer, and it is considered as the most significant contributor to cancer related mortality and morbidity [19] . Tumor metastasis is a very complex process, which involves various stages and several cytophysio logical changes including invasion into the extracellular matrix, migration into bloodstream followed by the extravasate from the circulatory system and initiate colonize distant sites in secondary organ tissues.
Recently, identification of the gene expression during tumor progression has been the great significant of intense method for prognosis and therapy. At the first time, KAI1/ CD82 was discovered as a tumor metastasis suppressor in metastatic prostate cancer cells. KAI1 was later identified to be metastasis suppressor gene during tumor growth in several solid tumors. It has been shown that KAI1/CD82 suppresses metastasis by various mechanisms involving inhibition of invasion and motility, induction of apoptosis and senescence in response to extracellular stimuli [20] . Several studies revealed that there are an association between reduced expression of KAI1/CD82 and increasing metastatic ability in human malignant tumors such as bladder, cervical, ovarian, breast, prostate and hepatocellular carcinoma [21, 22] . The interactions of KAI1/CD82 with several molecules such as epidermal growth factor receptors, chemokines and integrins are likely to play a significant role in cell-cell interaction, signaling and motility of cells, which infer an important role of this gene [23, 24] . Other studies showed that Bax, Bad, Bcl2, PDGF, c-kit genes were differently regulated by imatinib mesylate [18, 24, 25] . In 2009, Weigel M. et al. found that combination of imatinib and vinorelbine induced apoptotic cell death in five human breast adenocarcinoma cells [26] . Fernandes B. et al. reported that treating of an animal model with imatinib resulted in 10-fold up regulation of KiSS-1 metastasis suppressor gene, which was then identified as a human metastatic suppressor gene [27] . The consequential finding in our study indicated that imatinib can up-regulate KAI1/CD82 gene expression in human breast cancer cell line which has not yet been reported. This is the first report depicting significant inhibition of proliferation and increased expression of KAI1/CD82 gene in breast cancer MCF-7 cells line. Therefore, imatinib remains a promising candidate for the treatment of breast cancer in the future.
In this study we demonstrated that treatment with imatinib for 24 h induces a dose-dependent inhibitory manner on the MCF-7 cells. Also, IM can induce up-regulation of KAI1/CD82 mRNA levels in MCF-7 in a dose-dependent manner. Based on these results, imatinib probably increases expression of KAI1/CD82 gene in breast cancer MCF-7 cells. Future subsequent clinical studies on animal tumor models are required to confirm our finding.
